Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P542: Long-term outcomes after switching from originator infliximab to biosimilar in paediatric-onset inflammatory bowel disease patients: a single centre prospective observational studyECCO '17 Barcelona
Year: 2017
Authors:

Kang B., Lee K., Choe Y.H.

Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Pediatrics, Seoul, South Korea

P543: Structured transition enhances clinical outcome without an increase in healthcare cost in adolescent patients with IBD: the UK TRANSIT studyECCO '17 Barcelona
Year: 2017
Authors:

McCartney S.*1, Lindsay J.2, Russell R.3, Gaya D.3, Shaw I.4, Murray C.5, Finney-Hayward T.6, Sebastian S.7

1University College London Hospitals NHS Foundation Trust, London, United Kingdom 2Barts Health NHS Trust, London, United Kingdom 3NHS Greater Glasgow and Clyde, Glasgow, United Kingdom 4Gloucestershire Hospitals NHS Foundation Trust, Gloucester, United Kingdom 5Royal Free London NHS Foundation Trust, London, United Kingdom 6AbbVie, Maidenhead, United Kingdom 7Hull and East Yorkshire Hospitals NHS Trust, Hull, United Kingdom

P544: Combination therapy of vedolizumab and a TNF antagonist in IBD patients with severe chronic active, therapy refractory disease courseECCO '17 Barcelona
Year: 2017
Authors:

Kuehbacher T.*1, Abu Hashem R.1, Langel N.1, Schreiber S.2, Drvarov O.1

1Asklepios Westklinikum Hamburg, Gastroenterology, Hamburg, Germany 2Christian Albrechts University Kiel, Department of Internal Medicine I, Kiel, Germany

P545: Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients in clinical remission: preliminary resultsECCO '17 Barcelona
Year: 2017
Authors:

Guerrero Puente L.N.*1, Iglesias Flores E.1, Benítez Cantero J.M.1, Cárdenas Aranzana M.J.2, Medina Medina R.1, Salgueiro Rodríguez I.1, Aguilar Melero P.1, Manzanares Martin B.3, García-Sánchez V.1

1Hospital Universitario Reina Sofía, Clinical Unit Of Gastroenterology, Cόrdoba, Spain 2Hospital Universitario Reina Sofía, Clinical Unit Of Pharmacy, Cόrdoba, Spain 3Hospital Universitario Reina Sofía, Service Of Immunology, Cόrdoba, Spain

P546: Which are the optimal adalimumab trough levels associated with biological remission in patients with inflammatory bowel disease?ECCO '17 Barcelona
Year: 2017
Authors:

Serra K.*1, Rodríguez-Alonso L.1, Padullés N.2, Rodríguez-Moranta F.1, Arajol C.1, Gilabert P.1, Rodríguez R.1, Bas J.3, Morandeira-Rego F.3, Santacana E.2, Padullés A.2, Guardiola J.1

1Hospital Universitari de Bellvitge, Department of Gastroenterology, Barcelona, Spain 2Hospital Universitari de Bellvitge, Department of Pharmacy, Barcelona, Spain 3Hospital Universitari de Bellvitge, Department of Immunology, Barcelona, Spain

P547: Is there an association between bariatric surgery and Crohn's disease?ECCO '17 Barcelona
Year: 2017
Authors:

Brcic I.*1, Todoroff A.2, Baumgartner K.2, Langner C.1, Gröchenig H.P.3

1Medical University of Graz, Institute of Pathology, Graz, Austria 2Krankenhaus Barmherzige Brüder, Department of Surgery, St. Veit an der Glan, Austria 3Krankenhaus Barmherzige Brüder, Internal Medicine, St. Veit an der Glan, Austria

P548: Hepatitis B virus reactivation in hepatitis B virus infected patients with inflammatory bowel disease receiving anti-tumor necrosis factor-alpha therapyECCO '17 Barcelona
Year: 2017
Authors:

Lee J.M.*1, Lee K.-M.1, Kim H.-S.2, Ye B.D.3, Park S.J.4, Park S.H.3, Im J.P.5, Jang B.I.6, Kim D.B.1

1The Catholic University of Korea, School of Medicine, St. Vincent's Hospital, Suwon, South Korea 2Yonsei University Wonju College of Medicine, Wonju, South Korea 3Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea 4Yonsei University College of Medicine, Seoul, South Korea 5Seoul National University College of Medicine, Seoul, South Korea 6Yeungnam University College of Medicine, Daegu, South Korea

P549: Effect of maintenance Ustekinumab on corticosteroid-free clinical outcomes in patients with Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Feagan B.G.*1, Gasink C.2, Pollack P.2, Jacobstein D.2, Gao L.-L.2, Johanns J.2, Miao Y.2, Targan S.3, Ghosh S.4

1Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ont., Canada 2Janssen Research & Development, LLC, Spring House, United States 3Cedars-Sinai Medical Center, Los Angeles, United States 4University of Birmingham, Birmingham, United Kingdom

P550: Clinical features of demyelination following anti-TNFα therapyECCO '17 Barcelona
Year: 2017
Authors:

Hendy P.1,2, Heerasing N.*1,2, Walker G.2, Heap G.1,2, Bewshae C.2, Kennedy N.1, Goodhand J.1, Martin R.3, Hobart J.4, Harrower T.5, Coles A.6, Ahmad T.1,2

1Royal Devon & Exeter NHS Foundation Trust, Department of Gastroenterology, Exeter, United Kingdom 2Royal Devon & Exeter NHS Foundation Trust, IBD Pharmacogenetics Research, Exeter, United Kingdom 3Gloucestershire Royal Hospital, Department of Neurology, Gloucester, United Kingdom 4Plymouth University, Peninsula Schools of Medicine and Dentistry, Plymouth, United Kingdom 5Royal Devon & Exeter NHS Foundation Trust, Department of Neurology, Exeter, United Kingdom 6Addenbrooke's Hospital, Department of Neurosciences, Cambridge, United Kingdom

P551: Smooth Seton® for perianal fistulas: a knot-less solutionECCO '17 Barcelona
Year: 2017
Authors:

Stellingwerf M.*1, de Groof J.1, Buskens C.1, Nerkens W.2, Horeman T.2, Bemelman W.1

1AMC, Surgery, Amsterdam, Netherlands 2MediShield B.V., Delft, Netherlands

P552: An online educational portal improves concerns of inflammatory bowel disease patients regarding pregnancy and medicationECCO '17 Barcelona
Year: 2017
Authors:

Sutton R.1, Wierstra K.2, Ambrosio L.3, Dieleman L.3, Fedorak R.N.3, Halloran B.3, Kroeker K.I.3, Wong K.3, Berga K.-A.4, Huang V.W.*5

1University of Alberta, Department of Medicine, Edmonton, Canada 2University of Alberta, Edmonton, Canada 3University of Alberta, Gastroenterology, Edmonton, Canada 4MacEwan University, Edmonton, Canada 5University of Alberta, Medicine, Edmonton, Canada

P553: Long-term outcomes of seton drainage for perianal fistulizing Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Banayan E., Zagihyan K., Fleshner P.

Cedars-Sinai Medical Center, Colorectal Surgery, Los Angeles, United States

P554: Impact of real world home based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: one year results of pragmatic randomized trialECCO '17 Barcelona
Year: 2017
Authors:

Atreja A., Khan S., Otobo E., Rogers J., Ullman T., Grinspan A., Itzkowitz S., Maser E., Cohen B., Colombel J.-F., Sands B.

Icahn School of Medicine at Mount Sinai, Department of Medicine, New York City, United States

P555: Systematic review of interventions for chronic abdominal pain management in inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Norton C.1, Czuber-Dochan W.2, Artom M.2, Sweeney L.*2, Hart A.3

1King's College, Faculty of Nursing and Midwifery, London, United Kingdom 2King's College London, Faculty of Nursing and Midwifery, London, United Kingdom 3St Marks Hospital, Gastroentrology, London, United Kingdom

P556: Female Crohn's disease patients and ulcerative colitis patients on biologic therapy are most disabledECCO '17 Barcelona
Year: 2017
Authors:

Spizzo P.

St Vincent's Hospital Melbourne, Victoria, Australia

P557: Utility of “trough levels” adalimumab determination in patients with inflammatory bowel disease. Estimation of individual pharmacokinetic parameters through population pharmacokinetic modelECCO '17 Barcelona
Year: 2017
Authors:

Juan G.*1, Alvariño A.2, Mora M.3, Oltra L.3, Maroto N.3, Ferrer I.3, Hinojosa E.3, Hinojosa M.D.3, Hinojosa J.3

1Hospital de Manises, Department of Pharmacy, Manises, Spain 2Hospital de Manises, Department of Labratory, Manises, Spain 3Hospital de Manises, IBD Unit, Manises, Spain

P558: The SF-36® Health Survey distinguishes disease burden on functioning and well-being between patients with active vs inactive ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Rubin D.T.*1, Panés J.2, Lindsay J.O.3, Vermeire S.4, Yarlas A.5, Bayliss M.5, Cappelleri J.C.6, Maher S.5, Bushmakin A.G.6, Chen L.A.7, Manuchehri A.8, Healey P.6

1The University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, United States 2Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain 3Centre for Immunobiology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom 4Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium 5Optum, Lincoln, RI, United States 6Pfizer Inc, Groton, CT, United States 7New York University School of Medicine, New York, NY, United States 8Pfizer Ltd, Tadworth, United Kingdom

P559: Treatment goals in IBD: a perspective from patients and their partnersECCO '17 Barcelona
Year: 2017
Authors:

Peek-Kuijt N., Aantjes M., Verwey M., van der Meulen-de Jong A., Maljaars P.

Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands

P560: Trough levels at induction: impact on long term response when re-initiating infliximabECCO '17 Barcelona
Year: 2017
Authors:

Liefferinckx C.*1, Minsart C.2, Toubeau J.-F.3, Cremer A.4, Amininejad L.4, Quertinmont E.2, Devière J.4, Gils A.5, Van Gossum A.4, Franchimont D.4

1Université libre de bruxelles, Laboratory of Experimental Gastroenterology, Brussels, Belgium 2Université libre de Bruxelles, Laboratory of Experimental Gastroenterology, Brussels, Belgium 3Université de Mons, Department of Electrical Engineering, Mons, Belgium 4Erasme Hospital, Gastro-enterology, Brussels, Belgium 5KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium

P561: Can we predict adherence to treatment in IBD patients?ECCO '17 Barcelona
Year: 2017
Authors:

Naftali T.*1, Ein Dor A.2,3, Ruhimovich N.4, Shitrit A.B.5, Sklerovsky Benjaminov F.2,4, Matalon S.2,3, Shirin H.3,6, Konikoff F.M.1,2, Broide E.3,6

1Meir medical center, Gastroenterology, Kfar Saba, Israel 2Tel Aviv university Sackler school of medicin, internal medicine, Tel Aviv, Israel 3Assaf Harofeh Medical Center, The Kamila Gonczarowski institute of Gastroenterology Assaf Harofeh Medical Center, Zerifin, Israel 4Meir Medical Center, Department of Gastroenterology & Hepatology, Kfar Saba, Israel 5Shaare Zedek Medical Center, Department of Gastroenterology and Digestive Diseases, Jerusalem, Israel 6Tel Aviv university Sackler school of medicin, internal medicine, Tel aviv, Israel